$8.05
arrow_drop_down9.55%Key Stats | |
---|---|
Open | $8.92 |
Prev. Close | $8.90 |
EPS | -1.28 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 7.51 | 9.18 |
52 Week Range | 2.18 | 13.68 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.28 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
2 Potentially High-Reward Growth Stocks to Buy Right Now
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia